Europe Psychedelic Drugs Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 25
1.1 OBJECTIVES OF THE STUDY 25
1.2 MARKET DEFINITION 25
1.3 OVERVIEW OF EUROPE PSYCHEDELIC DRUGS MARKET 25
1.4 LIMITATIONS 27
1.5 MARKETS COVERED 27
2 MARKET SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 CURRENCY AND PRICING 32
2.5 DBMR TRIPOD DATA VALIDATION MODEL 33
2.6 MULTIVARIATE MODELLING 36
2.7 TYPE LIFELINE CURVE 36
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.9 DBMR MARKET POSITION GRID 38
2.10 MARKET END USER COVERAGE GRID 39
2.11 VENDOR SHARE ANALYSIS 40
2.12 SECONDARY SOURCES 41
2.13 ASSUMPTIONS 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHT 46
4.1 PIPELINE ANALYSIS 47
4.2 PESTEL ANALYSIS 49
4.3 PORTER'S FIVE FORCES MODEL 50
5 REGULATORY FRAMEWORK: EUROPE PSYCHEDELIC DRUGS MARKET 51
5.1 REGULATORY SCENARIO IN THE U.S. 51
5.2 REGULATORY SCENARIO IN THE U.K. 52
5.3 REGULATORY SCENARIO IN INDIA 53
5.4 REGULATORY SCENARIO IN UAE 53
5.5 REGULATORY SCENARIO IN AFRICA 54
5.6 REGULATORY SCENARIO IN BRAZIL 54

6 MARKET OVERVIEW 56
6.1 DRIVERS 58
6.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS TO TREAT DEPRESSION 58
6.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS 60
6.1.3 RISING AWARENESS TOWARD MENTAL HEALTH 63
6.1.4 ONGOING CLINICAL TRIALS 64
6.1.5 RISE IN PRODUCT APPROVALS 65
6.2 RESTRAINTS 65
6.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS 65
6.2.2 HIGH COST OF PSYCHEDELIC DRUGS 68
6.2.3 PATENT EXPIRY OF PSYCHEDELIC DRUGS 69
6.3 OPPORTUNITIES 70
6.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS 70
6.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY 72
6.3.3 UPCOMING REHABILITATION CENTERS 73
6.3.4 AVAILABILITY OF CERTIFIED HEALTHCARE PROFESSIONALS 74
6.4 CHALLENGES 74
6.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS 74
6.4.2 RISE IN ILLEGAL ALTERNATIVES 76
6.4.3 AVAILABILITY OF OTHER TREATMENT OPTIONS 76
7 COVID-19 IMPACT ON THE EUROPE PSYCHEDELIC DRUGS MARKET 77
7.1 IMPACT ON PRICE 77
7.2 IMPACT ON DEMAND 77
7.3 IMPACT ON SUPPLY CHAIN 78
7.4 STRATEGIC DECISIONS FOR MANUFACTURERS 78
7.5 CONCLUSION 79
8 EUROPE PSYCHEDELIC DRUGS MARKET, BY TYPE 80
8.1 OVERVIEW 81
8.2 EMPATHOGENS 84
8.3 DISSOCIATIVES 85
8.4 OTHERS 86
9 EUROPE PSYCHEDELIC DRUGS MARKET, BY SOURCE 87
9.1 OVERVIEW 88
9.2 SYNTHETIC 91
9.3 NATURAL 92

10 EUROPE PSYCHEDELIC DRUGS MARKET, BY DRUGS 93
10.1 OVERVIEW 94
10.2 GAMMA-HYDROXYBUTYRIC ACID 97
10.3 KETAMINE 98
10.4 PSILOCYBIN 99
10.5 OTHERS 100
11 EUROPE PSYCHEDELIC DRUGS MARKET, BY APPLICATION 101
11.1 OVERVIEW 102
11.2 NARCOLEPSY 105
11.3 TREATMENT RESISTANT DEPRESSION 106
11.4 MAJOR DEPRESSIVE DISORDER 107
11.5 OPIATE ADDICTION 108
11.6 POST-TRAUMATIC STRESS DISORDER 109
11.7 OTHERS 110
12 EUROPE PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION 111
12.1 OVERVIEW 112
12.2 ORAL 115
12.3 INHALATION 116
12.4 INJECTABLE 117
13 EUROPE PSYCHEDELIC DRUGS MARKET, BY END USER 118
13.1 OVERVIEW 119
13.2 HOSPITALS 122
13.3 SPECIALTY CLINICS 123
13.4 HOMECARE 124
13.5 OTHERS 125
14 EUROPE PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL 126
14.1 OVERVIEW 127
14.2 HOSPITALS PHARMACY 130
14.3 RETAIL PHARMACY 131
14.4 ONLINE PHARMACY 132

15 EUROPE PSYCHEDELIC DRUGS MARKET, BY REGION 133
15.1 EUROPE 134
15.1.1 GERMANY 143
15.1.2 U.K. 145
15.1.3 FRANCE 148
15.1.4 ITALY 150
15.1.5 SPAIN 153
15.1.6 RUSSIA 155
15.1.7 POLAND 158
15.1.8 SWITZERLAND 161
15.1.9 NETHERLANDS 164
15.1.10 HUNGARY 167
15.1.11 AUSTRIA 170
15.1.12 NORWAY 173
15.1.13 IRELAND 176
15.1.14 BELGIUM 179
15.1.15 LITHUANIA 182
15.1.16 REST OF EUROPE 185
16 EUROPE PSYCHEDELIC DRUGS MARKET: COMPANY LANDSCAPE 186
16.1 COMPANY SHARE ANALYSIS: EUROPE 186
17 SWOT ANALYSIS 187
18 COMPANY PROFILE 188
18.1 JAZZ PHARMACEUTICALS, INC. 188
18.1.1 COMPANY SNAPSHOT 188
18.1.2 REVENUE ANALYSIS 189
18.1.3 COMPANY SHARE ANALYSIS 189
18.1.4 PRODUCT PORTFOLIO 189
18.1.5 RECENT DEVELOPMENTS 190
18.2 PFIZER INC. 191
18.2.1 COMPANY SNAPSHOT 191
18.2.2 REVENUE ANALYSIS 191
18.2.3 COMPANY SHARE ANALYSIS 192
18.2.4 PRODUCT PORTFOLIO 192
18.2.5 RECENT DEVELOPMENTS 192

18.3 F. HOFFMANN- LA ROCHE LTD 193
18.3.1 COMPANY SNAPSHOT 193
18.3.2 REVENUE ANALYSIS 193
18.3.3 COMPANY SHARE ANALYSIS 194
18.3.4 PRODUCT PORTFOLIO 194
18.3.5 RECENT DEVELOPMENT 194
18.4 JANSSEN EUROPE SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 195
18.4.1 COMPANY SNAPSHOT 195
18.4.2 COMPANY SHARE ANALYSIS 195
18.4.3 PRODUCT PORTFOLIO 196
18.4.4 RECENT DEVELOPMENT 196
18.5 AVADEL 197
18.5.1 COMPANY SNAPSHOT 197
18.5.2 PRODUCT PORTFOLIO 197
18.5.3 RECENT DEVELOPMENT 197
18.6 CELON PHARMA SA 198
18.6.1 COMPANY SNAPSHOT 198
18.6.2 PRODUCT PORTFOLIO 198
18.6.3 RECENT DEVELOPMENT 198
18.7 COMPASS 199
18.7.1 COMPANY SNAPSHOT 199
18.7.2 PRODUCT PORTFOLIO 199
18.7.3 RECENT DEVELOPMENTS 199
18.8 CYBIN CORP. 200
18.8.1 COMPANY SNAPSHOT 200
18.8.2 PRODUCT PORTFOLIO 200
18.8.3 RECENT DEVELOPMENTS 200
18.9 ENTHEON BIOMEDICAL CORP 201
18.9.1 COMPANY SNAPSHOT 201
18.9.2 PRODUCT PORTFOLIO 201
18.9.3 RECENT DEVELOPMENT 201
18.10 GH RESEARCH 202
18.10.1 COMPANY SNAPSHOT 202
18.10.2 PRODUCT PORTFOLIO 202
18.10.3 RECENT DEVELOPMENT 202
18.11 HIKMA PHARMACEUTICALS PLC 203
18.11.1 COMPANY SNAPSHOT 203
18.11.2 REVENUE ANALYSIS 203
18.11.3 PRODUCT PORTFOLIO 204
18.11.4 RECENT DEVELOPMENTS 204
18.12 NRX PHARMACEUTICALS, INC. 205
18.12.1 COMPANY SNAPSHOT 205
18.12.2 PRODUCT PORTFOLIO 205
18.12.3 RECENT DEVELOPMENT 205
18.13 PHARMATHER HOLDINGS LTD. 206
18.13.1 COMPANY SNAPSHOT 206
18.13.2 PRODUCT PORTFOLIO 206
18.13.3 RECENT DEVELOPMENT 206
18.14 VERRIAN 207
18.14.1 COMPANY SNAPSHOT 207
18.14.2 PRODUCT PORTFOLIO 207
18.14.3 RECENT DEVELOPMENT 207
18.15 USONAINSTITUTE.ORG 208
18.15.1 COMPANY SNAPSHOT 208
18.15.2 PRODUCT PORTFOLIO 208
18.15.3 RECENT DEVELOPMENT 208
19 QUESTIONNAIRE 209
20 RELATED REPORTS 213